logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jianming Xu

chinese pla general hospital
H指数:56
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)

一线替雷利珠单抗联合化疗对比安慰剂联合化疗在不可切除的局部晚期/转移性食管鳞状细胞癌中的应用：一项随机III期试验（RATIONALE-306）3年生存随访的最低数据

Nature Communications
IF15.7
2026-09-030
OAAI
Harry H. Yoon; Ken Kato; Eric Raymond; Richard Hubner; Yongqian Shu; Yueyin Pan; Sook Ryun Park; Takashi Kojima; Chen-Yuan Lin; Lucjan Wyrwicz; David Tougeron; Ryu Ishihara; Kaijun Wang; Yanyan Peng; Jianming Xu
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial☆

177Lu-Dotatate与长效高剂量奥曲肽治疗晚期、G1-G2级、分化良好的胃肠胰神经内分泌肿瘤（XT-XTR008-3-01）：一项开放标签、随机、III期临床试验☆

Annals of Oncology
IF65.4
2025-10-180
PRE
J. Xu; J. Chen; S. Song; L. Song; R. Wang; J. Hao; X. Du; D. Cao; Y. Gao; X. Lan; A. Yang; W. Miao; H. Xu; Y. Chen; L. Li; H. Shi; X. Yuan; F. Ye; J. Wang; N. Xu; X. Han; X. Li; R. Huang; T. Zhang; E. Li; R. Wang; Y. Zhou; H. Chen; X. Zhu; J. Zhao; X. Su; Y. Cui; P. Ren; P. Wang
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial

帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性晚期胃癌：来自随机KEYNOTE-811试验的健康相关生活质量分析

ESMO Open
IF8.3
2025-09-300
OAAI
Y.Y. Janjigian; A. Kawazoe; J. Xu; S. Lonardi; J.-P. Metges; L.S. Wyrwicz; L. Shen; Y. Ostapenko; M. Bilici; M.A. Lowery; A. Valderrama; Y. Guan; K. Li; C.-S. Shih; S.Y. Rha
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab (PD-1抑制剂) 联合贝伐单抗 (贝伐单抗生物仿制药) 作为晚期肝细胞癌的一线治疗: 一项随机2/3期试验

Signal Transduction and Targeted Therapy
IF52.7
2025-08-060
OAAI
Chuanhua Zhao; Yanqiao Zhang; Gang Wang; Jinfang Zheng; Weiqing Chen; Zheng Lu; Li Zhuang; Shanzhi Gu; Lei Han; Zhendong Zheng; Zujiang Yu; Yongsheng Yang; Hongmei Sun; Xiaoyong Wei; Ying Cheng; Hailan Lin; Bo Zhu; Guicheng Wu; Kaijian Lei; Wei Wang; Yuwen Wang; Kehe Chen; Ximing Xu; Cuiping Zheng; Yanzhi Bi; Sijuan Ding; Jingdong Zhang; Wei Li; Hailong Liu; Jun Wang; Xianling Liu; Yangfeng Du; Lianming Cai; Jingran Wang; Zhanxiong Luo; Baocai Xing; Jie Shen; Lin Yang; Jianbing Wu; Ou Jiang; Zhigang Peng; Xiuli Liu; Bangwei Cao; Liangfang Shen; Aibing Xu; Aimin Li; Shaojun Chen; Ting Fu; Jian Chen; Chuan Jin; Lei Zhang; Jun Lv; Chengwu Zhang; Xiaoman Zhang; Yu Wang; Huo Su; Qiang Zhou; Wenlin Gai; Liangzhi Xie; Jianming Xu
Fruquintinib in less pretreated patients: multivariate profile-matching analysis of FRESCO-2 to FRESCO

fruquintinib 在较少预治疗患者中的研究：FRESCO-2 与 FRESCO 的多变量配型匹配分析

European Journal of Cancer
IF7.1
2025-07-130
OA
Arvind Dasari; Cathy Eng; Sara Lonardi; Rocio Garcia-Carbonero; Toshiki Masuishi; Chiara Cremolini; François Ghiringhelli; Joleen Hubbard; Tanios Bekaii-Saab; Jeremy Jones; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Yanhong Deng; Ying Yuan; Wei Wei; Jianchang Lin; Lucy Chen; Zhao Yang; Jin Li
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析

ADVANCES IN THERAPY
IF4
2025-03-010
OAAI
Xu, Jianming; Kato, Ken; Hubner, Richard; Park, Sook Ryun; Kojima, Takashi; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Wu, Hongqian; Wang, Lei; Yan, Sebastian; Shi, Jingwen; Kadva, Alysha; Yoon, Harry H.
Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
BIOSCIENCE TRENDS
IF5
2024-12-310
OA
Tang, Haowen; Zhang, Wenwen; Cao, Junning; Cao, Yinbiao; Bi, Xinyu; Zhao, Haitao; Zhang, Ze; Liu, Zhe; Wan, Tao; Lang, Ren; Sun, Wenbing; Du, Shunda; Yang, Yongping; Lu, Yinying; Zeng, Daobing; Wu, Jushan; Duan, Binwei; Lin, Dongdong; Li, Fei; Meng, Qinghua; Zhou, Jun; Xing, Baocai; Tian, Xiaodong; Zhu, Jiye; Gao, Jie; Hao, Chunyi; Wang, Zhiqiang; Duan, Feng; Wang, Zhijun; Wang, Maoqiang; Liang, Bin; Chen, Yongwei; Xu, Yinzhe; Li, Kai; Li, Chengang; Hu, Minggen; Wang, Zhaohai; Cai, Shouwang; Ji, Wenbin; Xia, Nianxin; Zheng, Wenheng; Wang, Hongguang; Li, Gong; Zhu, Ziman; Huang, Zhiyong; Zhang, Wanguang; Tao, Kaishan; Liang, Jun; Zhang, Keming; Dai, Chaoliu; Li, Jiangtao; Qiu, Qiu; Guo, Yuan; Wu, Liqun; Ding, Weibao; Zhu, Zhenyu; Gu, Wanqing; Cao, Jingyu; Wang, Zusen; Tian, Lantian; Ding, Huiguo; Li, Guangming; Zeng, Yongyi; Wang, Kui; Yang, Ning; Jin, Haosheng; Chen, Yajin; Yang, Yinmo; Xiu, Dianrong; Yan, Maolin; Wang, Xiaodong; Han, Quanli; Jiao, Shunchang; Tan, Guang; Wang, Jizhou; Liu, Lianxin; Song, Jinghai; Liao, Jiajie; Zhao, Hong; Li, Peng; Song, Tianqiang; Wang, Zhanbo; Yuan, Jing; Hu, Bingyang; Yuan, Yufeng; Zhang, Meng; Sun, Shuyang; Zhang, Jialin; Wang, Wentao; Wen, Tianfu; Yang, Jiayin; Du, Xilin; Peng, Tao; Xia, Feng; Liu, Zuojin; Niu, Weibo; Liang, Ping; Xu, Jianming; Zhao, Xiao; Zhu, Min; Wang, Huaizhi; Kuang, Ming; Shen, Shunli; Cui, Xing; Zhou, Jinxue; Liu, Rong; Sun, Huichuan; Fan, Jia; Chen, Xiaoping; Zhou, Jian; Cai, Jianqiang; Lu, Shichun
Comparison of Jinzhen oral liquid and ambroxol hydrochloride and clenbuterol hydrochloride oral solution in the treatment of acute bronchitis in children: A multicenter, non-inferiority, prospective, randomized controlled trial

金珍口服液与氨溴索氢氯盐和克仑特罗氢氯盐口服溶液在儿童急性支气管炎治疗中的比较：一项多中心、非劣效性、前瞻性、随机对照试验

ACTA PHARMACEUTICA SINICA B
IF14.6
2024-12-010
OAAI
Fan, QH; Wu, CM; Du, YW; Wang, BY; Xie, YM; Zhang, ZL; Su, WQ; Wang, ZZ; Xu, CC; Li, XK; Ding, Y; An, XJ; Chen, J; Xiao, YY; Yu, R; Li, N; Wang, J; Teng, YQ; Lv, HF; Yang, N; Wen, YL; Huang, XL; Pan, W; Liu, YF; Xi, XQ; Zhao, QY; Liu, CS; Xu, J; Zhang, HT; Zhuo, L; Rong, QQ; Xia, Y; Shen, Q; Li, S; Wang, JH; Wu, SX
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
LIVER CANCER
IF9.1
2024-10-220
OAAI
Yang, Yu; Sun, Juxian; Cai, Jianqiang; Chen, Minshan; Dai, Chaoliu; Wen, Tianfu; Xia, Jinglin; Ying, Mingang; Zhang, Zhiwei; Zhang, Xuewen; Fang, Chihua; Shen, Feng; An, Ping; Cai, Qingxian; Cao, Jingyu; Zeng, Zhen; Chen, Gang; Chen, Juan; Chen, Ping; Chen, Yongshun; Shan, Yunfeng; Dang, Shuangsuo; Guo, Wei-Xing; He, Jiefeng; Hu, Heping; Huang, Bin; Jia, Weidong; Jiang, Kexiang; Jin, Yan; Jin, Yongdong; Jin, Yun; Li, Gong; Liang, Yun; Liu, Enyu; Liu, Hao; Peng, Wei; Peng, Zhenwei; Peng, Zhiyi; Qian, Yeben; Ren, Wanhua; Shi, Jie; Song, Yusheng; Tao, Min; Tie, Jun; Wan, Xueying; Wang, Bin; Wang, Jin; Wang, Kai; Wang, Kang; Wang, Xin; Wei, Wenjing; Wu, Fei-Xiang; Xiang, Bangde; Xie, Lin; Xu, Jianming; Yan, Mao-Lin; Ye, Yufu; Yue, Jinbo; Zhang, Xiaoxun; Zhang, Yu; Zhang, Aibin; Zhao, Haitao; Zhao, Weifeng; Zheng, Xin; Zhou, Hongkun; Zhou, Huabang; Zhou, Jun; Zhou, Xinmin; Cheng, Shu-Qun; Li, Qiu
MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician's choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)

MK-2870-015：一项针对滋养层抗原2（TROP2）导向的抗体偶联药物（ADC）sacituzumab tirumotecan（sac-TMT）与研究者选择的治疗方案（TPC）用于既往治疗过的转移性胃食管腺癌（GEA）的III期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Wainberg, Z. A.; Van Cutsem, E.; Shitara, K.; Janjigian, Y. Y.; Oh, D-Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; Tabernero, J.
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
EUROPEAN JOURNAL OF CANCER
IF7.1
2024-03-018
OAAI
Zhang, Panpan; Shi, Si; Xu, Jianming; Chen, Zhendong; Song, Lijie; Zhang, Xing; Cheng, Ying; Zhang, Yanqiao; Ye, Feng; Li, Zhiping; Yin, Fei; Ji, Dongmei; Gao, Heli; Li, Yi; Chen, Wei; Yang, Minjie; Weng, Desheng; Wu, Chunjiao; Ma, Yue; Sheng, Wang; Zhao, Yaqin; Yin, Xiaolei; Shen, Weina; Su, Weiguo; Shi, Michael; Fan, Songhua; Tan, Panfeng; Xu, Qian; Lu, Min; Shen, Lin
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
ANNALS OF ONCOLOGY
IF65.4
2024-02-0139
OA
Yan, X. Q.; Yey, M. J.; Zou, Q.; Chen, P.; He, Z. S.; Wu, B.; He, D. L.; He, C. H.; Xue, X. Y.; Ji, Z. G.; Chen, H.; Zhang, S.; Liu, Y. P.; Zhang, X. D.; Fu, C.; Xu, D. F.; Qiu, M. X.; Lv, J. J.; Huang, J.; Ren, X. B.; Cheng, Y.; Qin, W. J.; Zhang, X.; Zhou, F. J.; Ma, L. L.; Guo, J. M.; Ding, D. G.; Wei, S. Z.; He, Y.; Guo, H. Q.; Shi, B. K.; Liu, L.; Liu, F.; Hu, Z. Q.; Jin, X. M.; Yang, L.; Zhu, S. X.; Liu, J. H.; Huang, Y. H.; Xu, T.; Liu, B.; Sun, T.; Wang, Z. J.; Jiang, H. W.; Yu, D. X.; Zhou, A. P.; Jiang, J.; Luan, G. D.; Jin, C. L.; Xu, J.; Hu, J. X.; Huang, Y. R.; Guo, J.; Zhai, W.; Sheng, X. N.

研究方向

暂未获取到该数据
Y
Yuxian Bai
H 指数:59论文数:366被引数:1.9万
S
Shukui Qin
H 指数:76论文数:578被引数:5.1万
H
Hongming Pan
H 指数:63论文数:371被引数:2.3万
L
Lin Shen
H 指数:62论文数:827被引数:2.6万
徐
徐瑞华
H 指数:104论文数:1,467被引数:5.3万
T
Tianshu Liu
H 指数:49论文数:399被引数:1.6万
程
程颖
H 指数:84论文数:1,042被引数:4.4万
N
Nong Xu
H 指数:30论文数:187被引数:7,557
W
Weiguo Su
H 指数:23论文数:151被引数:2,592
R
Rongrui Liu
H 指数:14论文数:72被引数:1,205